Why does the FDA have a 75-year delay for releasing Pfizer data?

Albert Bourla expressed uncertainty about the FDA's specific reasons for the lengthy data release timeline, suggesting it might be due to bureaucratic processes like reviewing a limited number of pages per day.

Does the revolving door between Pfizer, FDA, and CDC affect drug approval?

Bourla stated he has zero doubts it doesn't affect unbiased regulation, citing time barriers and strict processes within agencies that ensure checks and balances. He noted regulators are typically conservative but unbiased.

How can Pfizer regain public trust after past issues and general skepticism towards Big Pharma?

Reputation is earned back slowly through consistent ethical behavior and demonstrating the value of science, especially in partnership with the private sector, Bourla believes.

What was the Bextra case, and how has Pfizer changed since then?

In 2009, Pfizer settled a $2.3 billion case related to illegal off-label marketing of the arthritis drug Bextra. Bourla stated that since 2003, the company has maintained a stellar record of compliance and fostered a culture of integrity.

Is Pfizer's marketing considered aggressive, and could it influence media coverage?

Bourla believes Pfizer's marketing is not aggressive, noting that ads are highly regulated and must include safety information. He stated Pfizer is careful with sponsorships, focusing on patient organizations to avoid perceived influence.

How was the COVID-19 vaccine developed so quickly and demonstrated as safe and effective?

The speed was achieved by condensing timelines, risking significant financial investment upfront, and expanding recruitment sites. The scientific process and safety protocols remained rigorous, similar to previous vaccine developments.

What is the safety profile of the Pfizer vaccine?

Bourla asserted that no medical product has been tested as extensively as the Pfizer vaccine, administered to hundreds of millions and constantly scrutinized by global health authorities, confirming its high safety.

Do children need to be vaccinated against COVID-19?

Yes, Bourla believes children aged 5-16 need to be vaccinated. He empathizes with parental fears but stresses the disease's risks and school disruptions outweigh the concerns, comparing it to the importance of polio vaccination.

What is Paxlovid and how does it work?

Paxlovid is a five-day oral treatment for COVID-19 that significantly reduces the risk of hospitalization and death. It aims to keep people out of hospitals, easing the burden on healthcare systems.

What are Pfizer's thoughts on Ivermectin for COVID-19?

Bourla expressed skepticism, stating that scientists at Pfizer see no reason for a parasitic drug like Ivermectin to act against COVID-19 and have not seen reliable peer-reviewed papers supporting its efficacy.

What gives you hope for the future of human civilization?

Human ingenuity and the continuous progress seen across various aspects like poverty reduction, human rights, science, and quality of life give Bourla hope. He believes humans will continue to create a better future.

Key Moments

Albert Bourla: Pfizer CEO | Lex Fridman Podcast #249

Lex Fridman

Science & Technology4 min read69 min video

Dec 18, 2021|374,351 views|10,369|5,092

agi ai ai podcast albert bourla artificial intelligence artificial intelligence podcast cdc corruption covid fda freedom government

Save to Pod

Key Moments

TL;DR

Pfizer CEO Albert Bourla discusses COVID vaccine development, transparency, trust, and the future.

Key Insights

The development of the COVID-19 vaccine is hailed as a great scientific accomplishment, despite being a source of division.

Pfizer took a significant financial risk by investing over $2 billion upfront for vaccine development, prioritizing speed and to address the pandemic.

The FDA's regulatory process is described as rigorous and detailed, with scientists of high caliber ensuring drug safety and efficacy.

Regaining public trust in the pharmaceutical industry requires consistent effort and transparent behavior, acknowledging past mistakes like the Bextra case.

The rapid development of the COVID-19 vaccine was achieved by condensing timelines and taking significant financial risks, not by compromising scientific processes.

Paxlovid, an antiviral treatment, is presented as a game-changer for managing COVID-19, significantly reducing hospitalizations and deaths.

Mandating vaccines is a difficult decision for public health officials, with debate on balancing public health with individual freedom.

THE TRIUMPH AND DIVISION OF VACCINE DEVELOPMENT

Albert Bourla, CEO of Pfizer, reflects on the development of the COVID-19 vaccine as a monumental scientific achievement offering hope. However, he acknowledges it has also become a significant source of societal division. Bourla emphasizes that while science has the power to save lives, the corrupting influence of power and money within institutions cannot be ignored. He advocates for critical thinking and avoiding blind allegiance to any authority, highlighting the human burden to discern truth amidst competing narratives.

THE HIGH-STAKES DECISION TO GO ALL IN

Bourla recounts the tense moments awaiting the Phase 3 trial results on November 8, 2020, describing the immense relief and liberation upon receiving positive news. He details Pfizer's decision to invest over $2.3 billion upfront in the vaccine's development, a significant departure from their usual incremental investment strategy. This 'all-in' approach was driven by the unprecedented nature of the pandemic and the urgent need for a solution.

BALANCING PROFIT AND PATIENT WELL-BEING

Regarding the company's dual mission of making money and doing good, Bourla asserts that focusing on genuine value creation for patients is the ultimate driver of financial success. He explains that the company's primary focus during the pandemic was on developing a solution for the global crisis, not on potential profits. This patient-centric approach, he believes, naturally leads to good returns.

NAVIGATING REGULATORY TRANSPARENCY AND TRUST

Bourla addresses concerns about regulatory processes, particularly the FDA's timeline for releasing data. While asserting confidence in the rigor and integrity of regulatory bodies like the FDA, EMA, and CDC, he acknowledges the potential for bureaucracy to slow down transparency. He stresses that while the processes are well-defined and data is released by law, communication failures can exacerbate public distrust, especially when malicious actors exploit fear for their gain.

ADDRESSING PAST MISTAKES AND REBUILDING REPUTATION

The conversation touches upon Pfizer's past settlement in 2009 for illegal marketing practices related to the drug Bextra. Bourla acknowledges this as a significant failure born from actions in 2003, emphasizing that considerable changes and cultural reforms have occurred since then. He highlights Pfizer's subsequent adherence to regulations and focuses on current efforts to rebuild trust through transparency and continued innovation.

THE ENGINEERING MARVEL OF RAPID VACCINE PRODUCTION

Bourla details the extraordinary feat of developing and manufacturing the COVID-19 vaccine at an unprecedented scale. He explains that the usual years-long process was condensed by taking immense financial risks, such as fast-tracking Phase 3 trials and expanding manufacturing capacity dramatically. This was achieved not just through engineering but by motivating people to achieve seemingly impossible goals, demonstrating remarkable human ingenuity.

ASSESSING VACCINE SAFETY AND EFFICACY

Addressing concerns about vaccine safety, Bourla assures that the Pfizer vaccine has undergone more rigorous testing and scrutiny than any medical product in history. He points to the continuous monitoring by global health authorities and the vast amount of data collected, reinforcing the vaccine's safety profile. He attributes public fear primarily to misinformation spread deliberately by those who profit from anxiety.

THE GAME-CHANGING POTENTIAL OF PAXLOVID

Bourla introduces Paxlovid, an antiviral treatment for COVID-19, as a significant development expected to revolutionize patient care. He explains that this course of pills, taken at home, can drastically reduce the need for hospitalization, thereby alleviating pressure on healthcare systems. The development of Paxlovid in just four months, despite the complexity of antiviral research, is highlighted as another testament to scientific and engineering capabilities.

NAVIGATING THE DEBATE ON VACCINE MANDATES

On the topic of vaccine mandates, Bourla acknowledges the complexity and sensitivity of the decision, deferring ultimate authority to public health officials. He shares his experience implementing a mandate at Pfizer, which successfully increased vaccination rates among employees. While recognizing the effectiveness of mandates, he also stresses the importance of the ongoing societal debate surrounding individual freedom and public health.

PROTECTING CHILDREN AND FOSTERING HOPE

Bourla expresses his belief in the necessity of vaccinating children, empathizing with parental concerns while emphasizing the risks of the disease. He argues that vaccination is crucial for controlling the spread in schools and protecting children's overall well-being. Despite challenges, he remains optimistic about human ingenuity and the capacity for progress, seeing science and innovation as key drivers for a better future.

Mentioned in This Episode

●Companies

●Organizations

●People Referenced

Common Questions

Pfizer invested over $2.3 billion to develop the COVID-19 vaccine, choosing to go 'all in' rather than pace the investment due to the urgent pandemic situation.

Topics

Health & Longevity Business & Entrepreneurship Pharmaceutical Industry Drug Safety Clinical Trials Vaccine Development Medicine & Clinical Public Trust Regulatory Affairs Antiviral Treatments

Mentioned in this video

People

Albert Bourla

CEO of Pfizer, discusses the development, safety, and rollout of the COVID-19 vaccine, as well as the company's broader mission and challenges.

Steve Jobs

Quoted by Albert Bourla on the meaning of life, emphasizing death as life's biggest invention that makes way for the new, and the importance of moving forward and creating.

Joe Rogan

Mentioned by Albert Bourla as a friend from Texas. He has reportedly highlighted Pfizer's aggressive marketing on mainstream media, prompting a discussion on the topic.

Jordan Peterson

Psychologist and author who suggested a question to Lex Fridman about the close relationship between Pfizer, FDA, and CDC.

Elon Musk

Mentioned as someone Lex Fridman spent time with, drawing a parallel between Musk's work with SpaceX and Pfizer's role in vaccine development, highlighting inspiration with less politics.

Lex Fridman

Host of the Lex Fridman Podcast, engages in a deep discussion with Albert Bourla about science, ethics, public trust, and the pharmaceutical industry.

John Campbell

Mentioned as someone who described a comparison between Paxlovid and Ivermectin, suggesting Ivermectin could be a savior.

Fedor Dostoevsky

Mentioned for his quote 'Beauty will save the world,' used by Albert Bourla to express a positive outlook on civilization.

Oscar Wilde

Quoted at the end of the podcast: 'The truth is rarely pure and never simple.'

Supplements

Ivermectin

A parasitic drug discussed in comparison to Paxlovid. Bourla expresses skepticism about its efficacy against COVID-19, citing a lack of reliable scientific papers.

Paxlovid

Pfizer's antiviral pill for COVID-19, described as a 'game-changer' with high efficacy in preventing hospitalization and death, developed rapidly.

Companies

Pfizer

The pharmaceutical company whose CEO, Albert Bourla, is interviewed. Discussed extensively regarding vaccine development, marketing, regulatory issues, and public trust.

BioNTech

Co-developer of the Pfizer-BioNTech COVID-19 vaccine. Mentioned in the context of the vaccine's development cost.

Organizations

FDA

The US regulatory body is discussed extensively regarding data release timelines, approval processes, and its role in ensuring drug safety and efficacy.

CDC

Mentioned in the context of its relationship with Pfizer and the FDA, particularly concerning drug approval processes and potential conflicts of interest.

Drugs & Medications

Bextra

An arthritis drug illegally marketed by Pfizer, leading to a $2.3 billion settlement in 2009. Discussed as a past issue impacting Pfizer's reputation.